Drug Trial Radar · NCT04870905
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Last checked: Nov 20, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
May 1, 2024
Study completion May 1, 2026
Sponsor
- Lead sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Union hospital of Fujian Medical University; Zhujiang Hospital; Guangdong Provincial People's Hospital
- First posted
- May 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th) locoregionally-advanced nasopharyngeal carcinoma (LANPC). All the Patients will receive 3 cycles of induction chemotherapy with docetaxel and cisplatin and cisplatin based concurrent chemoradiotherapy (CCRT) plus adjuvant immunotherapy (tisleilizumab). All patients will receive intensity-modulated radiotherapy (IMRT). Tisleilizumab will begin 4-6 weeks after CCRT and continue every 3 weeks for 12 cycles.
Conditions
- Nasopharyngeal Neoplasms
Interventions
Tis-U-SolDrug
Tislelizumab 200mg will be given every 3 weeks for 12 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure-free survival (FFS)Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.